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THE TREATMENT OF SEPSIS PATIENTS WITH
OBJECTIVE:
An international phase III trial (PROWESS, N = 1690) assessed that treatment with drotrecogin alfa (activated) reduced 28-day mortality among patients with severe sepsis. In the present study, cost effectiveness analyses are performed of this therapy in the treatment of severe sepsis (SS) and severe sepsis with multiple organ failure (SS/MOF) in Italy. METHODS: A decision model was developed based on PROWESS outcomes and resource use information. Absolute reduction in hospital mortality at day 28 was 6.0% (7.3% for patients with 2 or more organ dysfunctions at baseline (N = 1271)). Italyspecific cost data were applied to the resource use patterns of the European trial patients. Hospitalisation costs were based on published full daily cost estimates for ICU (€1,033) and the regular ward (€300). Assumed drotrecogin alfa (activated) cost in Italy is €261 per 5 mg vial, including VAT. Placebo arm cost of standard care includes €1,580 for Anti-thrombin III (ATIII) which is often used for treatment of sepsis patients in Italy but which has not shown a reduction in mortality in major trials (7,392 U ATIII per patient at €381 per 1,000 U (for 56% patients (from an expert panel)). Italian Life Tables were used to estimate life expectancy; which was adjusted for effects of severe sepsis. RESULTS: The estimated incremental cost per life year gained for drotrecogin alfa (activated) is €13,436 for SS (€17,148 discounting life years at 3%) and for SS/MOF is €9,660 (€12,284). CONCLUSIONS: A rule-of-thumb maximum acceptable value for a life year gained is about €50,000. Another suggested standard, the per capita GDP, would be about €20,000 for Italy. Both such amounts by far exceed the amount here reported for drotrecogin alfa (activated), which appears to be cost effective for the treatment of patients with severe sepsis, and severe sepsis with multiple organ failure, in Italy. 
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COST-EFFECTIVENESS OF DROTRECOGIN ALFA (ACTIVATED) IN THE TREATMENT OF SEVERE SEPSIS IN SPAIN
OBJECTIVES:
In the PROWESS trial (n = 1690), drotrecogin alfa (activated) (recombinant human Activated Protein C) significantly decreased the 28-day mortality in adults with severe sepsis compared with placebo (ARR 6,1%; p = 0,005). A cost-effectiveness analytical model was conducted to assess the efficiency of the drug in Spain in the trial population and in the expected approved indication (patients with multiple organ failures). METHODS: National Health Service perspective was used in the analysis. Effectiveness and resource use were obtained from data collected prospectively in the trial. Spanish costs data of patients treated in intensive care were applied. Direct costs assessed were drug cost, costs up to 28 days, and to final discharge. Life expectancy was estimated using actual age and sex, and Spanish life tables, and an adjustment for post discharge mortality associated with severe sepsis. Cost per hospital survivor and incremental hospital cost per life year gained (LYG) were calculated. LYG were not discounted in the base case analysis. Sensitivity analysis was applied adjusting for patterns of care, ICU costs, comorbidity and discount rate. RESULTS: In patients with multiple organ failure, drotrecogin alfa (activated) saved 7.3 additional lives in hospital per 100 treated patients at 28 days when compared with placebo (p < 0,05) (NNT = 14). The cost per hospital survivor was €119,857. Hospital survivors were estimated to live 12.2 years. The cost-effectiveness of drotrecogin alfa (activated) was €9,799 per LYG when compared with placebo (€13,594 per LYG for the trial population). The sensitivity analysis indicated that the largest influence on costs were the assumptions of the discount and reduction in life expectancy of patients. CON-CLUSIONS: In Spain, drotrecogin alfa (activated) has shown to be efficient in the treatment of severe sepsis. The incremental CE is better than many well-accepted and common healthcare interventions.
